Categories
Research Insights
NIH: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Seeks meritorious clinical trials proposing to explore and enable the development of safe and effective regenerative medicine interventions using adult stem cells.
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells.
Deadline: October 2, 2020